Acorda's drug treats nerve damage-related ED in preclinical test

Acorda Therapeutics' new neuregulin drug helped treat erectile dysfunction in rats with nerve damage, according to preclinical data the company presented at a recent conference. The ultimate goal would be to use the compound to benefit patients dealing with ED caused by cavernous nerve injury, which can commonly, and inadvertently, result from prostate surgery. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.